RareSearch

8.7

Excellent

376 reviews

Communication: 8.8

Timeliness: 8.9

Accuracy: 7.6

Staff: 8.8

Value: 8.9

Jonathan Spinka Jr.

🇲🇽 Mexico

8.9

Reviewed: July 3, 2024

- Stability Studies
- 18 months January 2023 - June 2024
- Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Colleen Hettinger

🇯🇵 Japan

9.2

Reviewed: January 10, 2024

- Data Visualization
- 3 weeks December 2023
- Pharmaceutical Company

Highly effective data visualization, easy to interpret and impactful.

The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.

Winston Cormier

🇸🇦 Saudi Arabia

5.4

Reviewed: October 3, 2024

- Process Development
- 14 weeks June - September 2024
- Biotech Company

Process development project faced delays, communication issues.

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.

Bruce Stracke

🇲🇽 Mexico

6.5

Reviewed: July 18, 2024

- Regulatory Submission
- 8 weeks May - July 2024
- Pharmaceutical Company

Regulatory submission was incomplete, required additional work.

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Lela Rempel V

🇨🇦 Canada

8.8

Reviewed: May 15, 2024

- Companion Diagnostics Development
- 16 weeks January - May 2024
- Pharmaceutical Company

High-quality companion diagnostics development, delivered on time.

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Kay Hoppe

🇰🇷 South Korea

5.6

Reviewed: February 20, 2024

- Clinical Data Management
- 8 weeks December 2023 - February 2024
- Biotech Company

Delayed delivery and lack of communication during the project.

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.

Lyle Reichert

🇨🇭 Switzerland

6.2

Reviewed: March 15, 2024

- Clinical Protocol Design
- 10 weeks January - March 2024
- Pharmaceutical Company

Inconsistent quality of deliverables, frequent revisions needed.

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Bryant Witting

🇮🇹 Italy

9.2

Reviewed: August 20, 2024

- Regulatory Strategy Consulting
- 4 weeks July - August 2024
- Biotech Startup

Thorough and strategic regulatory strategy consulting.

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Keith Stoltenberg IV